Rein Therapeutics
RNTX
43 hedge funds and large institutions have $18.9M invested in Rein Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 10 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.04% more ownership
Funds ownership: 1.82% → 1.85% (+0.04%)
0% more funds holding
Funds holding: 43 → 43 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
44% less capital invested
Capital invested by funds: $33.6M → $18.9M (-$14.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$502K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$204K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$65.9K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$63.9K |
| 5 |
Jane Street
New York
|
+$33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$528K |
| 2 |
Renaissance Technologies
New York
|
-$204K |
| 3 |
VF
Virtu Financial
New York
|
-$185K |
| 4 |
GW
GW & Wade
Wellesley,
Massachusetts
|
-$103K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$31K |
RNTX Hedge Fund Activity: Q4 2021 in Review
43 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2021, worth a combined $18.9M — down 44% from $33.6M a quarter earlier.
Fund positioning in RNTX was balanced in Q4 2021: 10 funds opened new positions, 10 closed out, 11 added to existing stakes and 9 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $502K. The largest seller was AJU IB Investment Company, exiting entirely with an estimated $528K sold.
- 43 institutional investors held Rein Therapeutics (RNTX) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $18.9M of Rein Therapeutics stock for Q4 2021, down 44% quarter-over-quarter.
- 10 funds opened new Rein Therapeutics positions in Q4 2021 and 10 closed out, a net change of 0 holders.
- The largest Rein Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $502K added.
- The largest Rein Therapeutics seller in Q4 2021 was AJU IB Investment Company, an estimated $528K sold.
Based on aggregated 13F filings for Q4 2021.